{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=18", "query": { "condition": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 930, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T00:16:56.074Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02250326", "title": "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "nab-paclitaxel IV", "type": "DRUG" }, { "name": "CC-486", "type": "DRUG" }, { "name": "Duravalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2015-01-07", "completion_date": "2023-08-17", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 9, "location_summary": "San Francisco, California • New Britain, Connecticut • Athens, Georgia + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Athens", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02250326" }, { "nct_id": "NCT00006049", "title": "ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 1, "location_summary": "Wilmington, Delaware", "locations": [ { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006049" }, { "nct_id": "NCT02289833", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2014-12-15", "completion_date": "2018-08-20", "has_results": true, "last_update_posted_date": "2019-08-07", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 5, "location_summary": "Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 2 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289833" }, { "nct_id": "NCT02959437", "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "INCB057643", "type": "DRUG" }, { "name": "INCB059872", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-02-27", "completion_date": "2020-03-02", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 8, "location_summary": "Duarte, California • La Jolla, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959437" }, { "nct_id": "NCT01041781", "title": "Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2010-02", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2018-07-23", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 400, "location_summary": "Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041781" }, { "nct_id": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Head and Neck Cancer", "Breast Cancer", "Colon Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Prostate Cancer", "Uterine Cancer", "Cervix Cancer", "Ovarian Cancer", "Kidney Cancer", "Bladder Cancer", "Thyroid Cancer", "Melanoma", "Sarcoma", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "SNS-101 (anti-VISTA)", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sensei Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-05-31", "completion_date": "2026-06-02", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05864144" }, { "nct_id": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Bladder Carcinoma", "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Renal Pelvis Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Bladder Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v6", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940299" }, { "nct_id": "NCT00016367", "title": "Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "1999-05-13", "completion_date": "2004-12-14", "has_results": false, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016367" }, { "nct_id": "NCT07636785", "title": "A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma (HCC)", "Metastatic Uveal Melanoma", "Renal Cell Carcinoma (RCC)", "Nonsmall Cell Lung Cancer", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "VMD-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Discovery, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 111, "start_date": "2026-07-16", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07636785" }, { "nct_id": "NCT00054210", "title": "Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "paclitaxel poliglumex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-01", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-15T00:16:56.074Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Mission Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054210" } ] }